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Cancer stem cells (CSCs) were isolated in multiple tumor types, including human glioblastomas, and although the presence of
surface markers selectively expressed on CSCs can be used to isolate them, no marker/pattern of markers are suﬃciently robust to
deﬁnitively identify stem cells in tumors. Several markers were evaluated for their prognostic value with promising early results,
however none of them was proven to be clinically useful in large-scale studies, leading to outstanding eﬀorts to identify new
markers. Given the heterogeneity of human glioblastomas further investigations are necessary to identify both cancer stem cell-
speciﬁc markers and the molecular mechanisms sustaining the tumorigenic potential of these cells to develop tailored treatments.
Markers for glioblastoma stem cells such as CD133, CD15, integrin-α6, L1CAM might be informative to identify these cells but
cannot be conclusively linked to a stem cell phenotype. Overlap of expression, functional state and morphology of diﬀerent
subpopulations lead to carefully consider the techniques employed so far to isolate these cells. Due to a dearth of methods and
markers reliably identifying the candidate cancer stem cells, the isolation/enrichment of cancer stem cells to be therapeutically
targeted remains a major challenge.
1.Introduction
The cancer stem cell hypothesis postulates that a small
subpopulation of cancer cells possessing self-renewal charac-
teristics are responsible for initiating and maintaining cancer
growth. According to the CSC model, the large populations
found in a tumor might represent diverse stages of diﬀer-
entiation. The biological characteristics shared by normal
stem cells (NSCs) and CSCs mainly involve self-renewal
and differentiation potential, survival ability, niche-speciﬁc
microenvironment requirements, and speciﬁc homing to
injury sites and may have important implications in terms
of new approaches to cancer. The identiﬁcation of new ther-
apeutic targets based on the CSC model represents a great
challenge.
Glioblastoma multiforme (WHO grade IV) is the most
aggressive among the brain tumors of adults and displays
striking morphologic variation among diﬀerent patients.
GBM contains a mixture cell populations with high propen-
sity to inﬁltrate throughout the brain (making complete
surgical resection impossible). It has been demonstrated
that the bulk of malignant cells in GBM is generated by
rare fractions of self-renewing, multipotent tumor-initiating
cells (CSCs) also called tumor-initiating cells or tumor-
propagating cells [1, 2] responsible for tumor growth and
recurrence and resistance to chemo- and radiotherapies [3].
Cancer stem cells generate tumors with the cardinal
features of the GBMs from which they derived, including
an inﬁltrative phenotype and histopathological features such
ashypercellularity,pseudopalisadingnecrosis,andangiogen-
esis. With the available tools, it is diﬃcult to isolate such
cells directly from biopsies since the bias derived from the
heterogeneity of the cellular composition of the specimen
will not give reliable and precise results. The approach of
processing and isolating the glioma stem cells from the
original tumor gives rise to inconsistencies among various
groups since it is not yet clear how stable is the phenotype of
the glioma stem cell.
Although in some tumors, such as breast, prostate,
pancreas, skin, colon, and blood cancer, the presence of
a slowly cycling and highly tumorigenic cell fraction is
recognized [4–12], no single antigen has been shown to2 Journal of Oncology
reliably segregate tumorigenic stem cells from the rest of the
tumor specimen.
The identiﬁcation of tumoral neural stem cells will pro-
vide a powerful tool to investigate the tumorigenic process in
the central nervous system and to develop therapies targeted
tothesecells.Thistakesonadditionalimportanceinthelight
of the demonstration that aberrant and multiple states of
diﬀerentiation may be present within the same tumor. To
date, current techniques have neither isolated nor deﬁned
proﬁles absolutely representative of a stem cell.
Although several markers may be informative towards
brain tumor stem cell identiﬁcation, the segregation of
universal, speciﬁc markers that might be reliably used to
distinguish a normal stem cell from a cancer stem cell as well
as a stem cell from a progenitor is still inadequate.
There is an overall lack of standardization regarding
methods for cell sorting and assessment of “stemness”
conﬁrmation. Moreover, there is a highly relevant debate
regarding thebestmethod forculturingthe glioma stemcells
isolated from human specimens: many groups proposed the
use of adherent monolayer cultures rather than nonadherent
cultures, since a homogeneous exposure to growth factors,
oxygen, and nutrients increases the possibility of obtaining a
more homogeneous cell population [13, 14]. On the other
hand, the sphere-forming assay has been used by many
laboratories as “the assay” to retrospectively isolate stem cells
from GBMs [15, 16] although its reliability and beneﬁts
are still under debate. It has been reported that under
appropriate conditions, cultured tumor stem cells derived
from primary human glioblastomas exhibit genotype, gene
expression proﬁle, and biology of their parental primary
tumors [17].
Neural stem cells were originally characterized and iden-
tiﬁed by their growth as neurospheres in a minimal medium
containing growth factors [15, 16], and there is a consider-
able body of evidence linking the ability of brain tumors to
give rise to multipassaged neurosphere cultures ex vivo with
patient clinical outcome [18].
This paper aims to approach the CSC hypothesis to
tackle the main challenge of this decade: the identiﬁcation
of reliable markers to defeat gliomas.
2. How PowerfulIsCD133 as a CSCsMarker in
Brain Tumors?
CD133 is considered a marker of stem cells in diverse normal
tissues and cancer types. Several studies demonstrated the
utility of CD133 in the enrichment of populations of cells
with stem-like properties, but there is also a large body of
evidence narrowing down its use as a stem cell marker. In
thissectionofthepaper,wehighlightthemostrelevantissues
concerning the role of CD133 as a stem cell marker.
Since the initial discovery in human CD34-positive
hematopoietic stem cells [19, 20], the expression of CD133
has been found in endothelial progenitors [21], myogenic
cells [22], prostatic epithelial stem cells [23, 24], and neural
stemcells[25–27].Cellswithextensiveself-renewalpotential
and the capacity to engraft, migrate, and undergo neural and
glial diﬀerentiation after orthotopic transplantation in mice
were isolated from human fetal brain and postmortem adult
brain tissues using FACS sorting with CD133 antibodies.
Indeed, evidence for the existence of CD133-expressing
cancer stem cell populations (clonogenic expansion in vitro
and tumor-initiating capacity in vivo)h a sb e e np r o v i d e d
in numerous tumor types including leukemia [28], prostate
cancer [29], colon cancer [30], lung cancer [31], hepatocel-
lular carcinoma [32], ependymoma [33], melanoma [34],
ovarian cancer [35], medulloblastoma, and glioblastoma
[2, 36]. With regard to brain tumors, Singh et al. [2, 36]
were the ﬁrst to describe a CD133-positive tumor cell
population, with stem cells characteristics that are capable of
self-renewal and exact recapitulation of the original tumor
when transplanted into immunodeﬁcient mouse brains.
They demonstrated that injection of as few as 100 CD133-
positive cells produced a tumor, whereas injection of 100.000
CD133-negative cells did not.
Quantitative analysis of CD133-positive cells by ﬂow
cytometry has generally found them to be present at low
and sometimes barely detectable levels in human gliomas,
glioma sphere cultures, and established glioma cell lines
[2, 37–40], consistent with the assumption that CSCs are a
rare cell population in solid tumors. However, some studies
have reported exceptionally high CD133-positive (20%–
60%) fractions in some human GBMs and/or glioma cell
lines[2,38,41],accordingtoimmunohistochemical ﬁndings
demonstrating that many GBMs contain more than 25%
CD133-positive cells [42].
Studies investigating the distribution and the prognostic
value of CD133 have reported inconsistent ﬁndings [42–49].
On one hand, a quantitative correlation of glioma grade with
the presence of CD133-positive cells within tumors and a
negative association between CD133 expression and patient
survival have been demonstrated in large cohorts of glioma
patients. Opposite results were obtained by Christensen et
al. [44] demonstrating no correlation between the presence
of tumor cells expressing CD133 and both tumor grade and
clinical outcome.
It is noteworthy that CD133 antigen has been used
t oe n r i c hf o rc a n c e rs t e mc e l l su s i n gﬂ o wc y t o m e t r y ,b u t
whether CD133 expression measured by mRNA and/or pro-
tein on immunoblotting or immunoﬂuorescence identiﬁes
cancerstemcellsisnotclearlyestablished.However,theasso-
ciation of CD133 mRNA and protein with poor prognosis
h a sbee nr e po rt edi ns ev e ra ls t u d i e s[50–52], including a very
recent one that analyses the prognostic impact of CD133
mRNA in 48 glioblastomas [50].
A great source of inconsistency in experimental results
mayderive fromtheuseofalternativeantibodies recognizing
diﬀerent CD133 protein epitopes. The most widely used
antibodies in CD133-related experiments are the CD133/1,
directedagainsttheAC133epitope,andtheCD133/2,direct-
ed against AC141 epitope. The AC133 and AC141 epitopes
are both glycosylated and have distinct spatial locations
[19, 20], but their molecular nature and their locations
on the CD133 protein have not been determined. Several
reports have documented overlap of the AC133- and AC141-
positive cell populations [19, 53, 54], although currentlyJournal of Oncology 3
there are no speciﬁc studies on the comparability of anti-
bodies recognizing these two diﬀerent epitopes. Indeed,
immunohistochemical staining of AC133 and AC141 epi-
topes poses a special challenge leading some researchers to
use alternative antibodies recognizing the CD133 protein. A
recent study demonstrated the inconsistent CD133 detection
when using diﬀerent primary CD133 antibody clones in
immunohistochemistry [55, 56].
In addition, the glycosylated nature of the AC133 epitope
has been questioned/discussed since CD133/1 antibody
can eﬀectively detect bacterially expressed, unglycosylated
CD133 [57].
Moreover, the exclusive detection of glycosylation-
dependent epitopes does not exclude the expression of
diﬀerentially or nonglycosylated CD133. Several studies have
demonstrated that the AC133 and AC141 epitopes can be
downregulated independently on the CD133 mRNA [53, 54]
and that the tissue distribution of CD133 mRNA is more
widespread than expression of the AC133 epitope. CD133
is expressed in diﬀerentiated epithelial cells in a variety of
tissues, though it has been used to identify normal stem cells
and cancer stem cells in many of these organs [58].
Thereareseverallinesofevidencetosuggesttheexistence
of CD133-negative glioma stem cells. First, CD133 is not
detectable in many fresh GBM specimens [38, 41, 59]
and in established glioma cell lines, which can nonetheless
form tumors in vivo [40, 41]. Second, cells with stem cell
characteristics and tumorigenic potential can be isolated
from CD133-negative gliomas as well as from CD133-
positivetumors.StemcellsisolatedfromCD133-positiveand
negative tumors may diﬀer in terms of other phenotypic
features, such as proliferation, invasiveness, and expression
proﬁles. A recent study based on gene expression proﬁle
analysis of CSC isolated from CD133-positive and CD133-
negative gliomas, has led to the deﬁnition of two diﬀerent
types of glioma stem cells: type 1 CSCs that are CD133 pos-
itive and grow as ﬂoating neurospheres and type 2 CSCs
whichareCD133negativeandgrowadherently.Interestingly,
type 1 cells were reminiscent of fetal neural stem cells and
type 2 cells genetically resemble adult neural stem cells
[60]. Third, both CD133-positive and CD133-negative cells
isolated from the same tumor specimen can be cultured
as neurospheres under serum-free conditions, and both
populations of cells are able to self-renew and to initiate
and propagate tumors upon xenotransplantation. Indeed,
CD133-negative cells are able to generate CD133-positive
progeny in vitro and in vivo [40, 61]. Chen et al. [61] recently
demonstrated the existence of three diﬀerent but coexisting
types of glioma stem cells, which diﬀer in CD133 expression:
type1(CD133-negativecellsabletogenerateCD133-positive
progeny), type 2 (CD133-positive cells able to generate
CD133-negative cells), and type 3 (CD133-negative which
generate only CD133-negative progeny). A hierarchy lineage
has been established between these three types of cells,
suggesting that it is a primordial CD133-negative cell that
gives rise to CD133-positive cells in some tumors.
Another important issue that needs to be considered in
the criticism of the role of CD133 as marker of stem cells is
its still unknown biological function.
3. Other PutativeMarkersof CSCs
Due in large part to conﬂicting results and irreproducibility
of experiments, a lot of disagreement exists regarding the use
of a speciﬁc marker or a combination of diﬀerent markers
to identify and isolate GBM CSCs. Besides that, there is an
additional complication: as shown by Quintana and col-
leagues in melanoma [62, 63], many markers expressed on
CSCs capable of distinguishing marker-positive and marker-
negative populations were also able to regenerate the original
expressionpattern.Theproblemofthedynamicityofmarker
expression oscillating in a cell-cycle-dependent manner or
becoming reexpressed after puriﬁcation is remarkable. An
emerging complication for the deﬁnition of therapeutic-
suitable markers is the oscillation between the quiescent and
activated states that cells undergo as well as the reversion
back to a more primitive state of committed progenitors.
The currently used surface proteins used for identifying
CSCs have not been shown to be necessary nor suﬃcient to
confer stem-cell-like properties.
4.L1CAM
The neuronal cell adhesion molecule L1CAM (L1, CD171) is
required for maintaining the growth and survival of CD133-
positive glioma cells with stem-like properties [64].
It has been shown that L1CAM regulates neural cell
growth, survival, and migration during central nervous
system development [65], but its role in the normal adult
n e r v o u ss y s t e mi sn o tw e l ld e ﬁ n e d .I nc a n c e r s ,i ti so v e r e x -
pressed in gliomas, in which it plays a role in tumor invasion
[66, 67] and other solid tumors [68–70], including colorectal
cancer where L1CAM functions as a prognostic indicator
[71].
In gliomas, L1CAM-positive and CD133-positive cells
cosegregate, and levels of L1CAM are higher in glioma
cells expressing CD133 than in normal neural progenitors.
However, L1CAM has not been used to identify and isolate
cancer stem cells. The self-renewal capacity and the tumori-
genic potential of L1CAM-positive and L1CAM-negative
subpopulations of glioma cells (even together with CD133)
have not been characterized yet.
Targeting L1CAM using lentiviral-mediated short hair-
pin RNA (shRNA) interference in CD133-positive glioma
cells inhibits growth and neurosphere formation of glioma
stem cells and induces their apoptosis, by regulating Olig2
expression with associated changes in the downstream eﬀec-
tors, p21WAF1/CIP1 [64]. Indeed, L1CAM-mediated signaling
confers radioresistance in glioma stem cells by enhancing
Mre11, Rad50, and Nbs1 (MRN) complex function through
Myc-NBS1-ATMaxisandleadingtoDNAcheckpointactiva-
tion and DNA repair [72].
Therefore, L1CAM is an attractive therapeutic target for
GBM therapy as it maintains GBM stem cells and regulates
their radioresistance.
Furthermore, it has not been determined whether
L1CAM itself may have a prognostic value in gliomas and
may be useful in immunohistochemical studies.4 Journal of Oncology
5.CD44 andId1
Several reports have shown the utility of the cell surface
marker CD44 in the identiﬁcation of cancer stem cells in dif-
ferent type of tumors such as breast cancer [4, 73], pancreas,
and prostate carcinomas [74, 75]. There is only one example
oftheuseofCD44asastemcellmarkeringlioblastoma[76].
Anido et al. show that CD44high/Id1high cells are localized
in the endothelial niches of the tumor tissue and possesses
stemcellcharacteristics.Remarkably,TFG-βcanregulatethis
population of cells, causing their depletion and preventing
tumor initiation and recurrence. Moreover, it is shown that
the high expression levels of both CD44 and Id1 are inversely
correlated with survival, conferring poor prognosis in GBM
patients.
A very recent paper [77] is providing new insights on
the role of Id1, a transcriptional regulator of self-renewal in
neural stem cells: high levels of Id1 could identify glioma
stem cells. The same group has previously identiﬁed Id1 as a
marker of pure stem cells since it has the tendency to reduce
its expression upon diﬀerentiation [78]. Immunostaining
and RT-PCR analysis conﬁrmed higher Id1 expression in
cells expressing stem-associated markers compared to cells
expressing progenitors-associated markers.
Employing a PDGF- and KRAS-driven murine models
of glioma, this group demonstrated that in these conditions
Id1high cells (represented by <1% of the total of tumor cells)
are characterized by high self-renewal capacity showed by an
increased percentage of cells able to form neurospheres and
giving rise to heterogeneous tumors in vivo. The authors,
while making a tight correlation between Id1 expression
and stemness, are disconnecting self-renewal capacity from
tumorigenic potential, since Id1low expressing cells show a
decreased sphere-forming capacity in vitro but can exten-
sively expand in vivo following transplantation.
6.CD15
Searching for alternative enrichment markers for stem cells
in brain tumors, several groups have identiﬁed CD15 as a
cell surface protein selectively expressed in cells with tumor
initiation capacity. CD15 (also known as SSEA-1 [stage-
speciﬁc embryonic antigen-1] or LeX) is a fucose-containing
trisaccharide expressed in adult neural stem/progenitor cells
[79] and embryonic stem cells during neural development
[80].
It has been demonstrated that in a mouse model of
medulloblastoma, the Patched mutant mouse, as well as a
subset of human tumors, a distinct subpopulation of cells
expressing CD15 is able to propagate tumors. In those
tumors, CD133 was not found to be expressed exclusively
within the stem cell compartment [81].
Inhumanglioblastomas,Sonetal.havefoundthatCD15
is an enrichment marker of stem cells in CD133-negative
tumors[41].Approximately40%ofthefreshlyisolatedGBM
specimens that they analyzed do not contain CD133-positive
cells. The selection of CD15-positive cells from CD133-
negative tumors enriches for cells able to form neurospheres
and colonies in soft agar, to diﬀerentiate into cells expressing
glial and neuronal markers, and to be highly tumorigenic
in vivo when serially transplanted in immunocompromised
mice. Furthermore, a hierarchical lineage has been estab-
lished between CD15-positive and -negative cells, since the
CD15-positive cells have the exclusive capacity to generate
the cell heterogeneity of the primary tumor.
Even so, as in the case for CD133, CD15 does not enrich
for a population of glioblastoma stem cells in every GBM
tumor, and the levels of CD15-positive cells vary greatly
among diﬀerent brain tumor specimens.
7.Integrinα6
Targeting integrin α6 in GBM cells inhibits self-renewal, pro-
liferation, and tumor formation capacity, adding insights to
theidentiﬁcationofgliomastemcells.Integrinα6,important
for the interaction with laminin-expressing endothelial cells
inthemicroenvironment,isacomponentoftheextracellular
matrix whose contact is important for glioma stem cells
maintenance. In the brain, laminin and integrin α6 regulate
neural stem cell growth [82] and CSC maintenance [83].
The integrin α6-laminin interaction was recently reported
to play an important role in the subventricular zone (SVZ)
of the lateral ventricles in the adult brain [84]. Biopsy
samplesfromglioblastomapatientsshowedthatintegrin-α6-
positive cells are localized in close proximity to the tumor
vasculature and often coexpressed the stem cell markers
CD133andnestin[85].FACSsortingforintegrinα6aloneor
in combination with CD133 led to enrichment of cells with
higher self-renewal capacity in vitro. Moreover, combining
CD133 and integrin α6 expression resulted in a higher
enrichment of glioma stem cells than CD133 expression
alone. Xenotransplantation of integrin-α6-positive cells in
thebrainsofimmunocompromised miceresultedin ahigher
incidence of secondary tumor formation and a reduced
survival than what was obtained with integrin α6n e g a t i v e
cells. Furthermore, integrin α6 depletion using short hairpin
RNA or treatment with integrin-blocking antibody reduced
both sphere growth in vitro and tumor formation in vivo
[85]. In addition to advancing our ability to identify CSCs in
gliomas, the ﬁndings also point to the potential of targeting
integrin α6 for antiglioblastoma therapy.
8.The StemCellNicheas
a Potential Marker’s Source
So far, the vast majority of the studies regarding cancer stem
cells have focused on the intrinsic properties of these cells;
however, it is recognized that normal stem cells of various
tissues are tightly regulated and sheltered from genotoxic
insults, by the microenvironment or stem cell niche. Sim-
ilarly to normal neural stem cells, the CSCs seem to have
potent angiogenic properties and can recruit vessels during
tumorigenesis. Moreover, it has been reported that the num-
ber of capillaries correlates with the GBM patients’ prognosis
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marker source may be the stem cell niche: there is, in fact,
the possibility to ﬁnd critical marker components in the
cell adhesion molecules since stem cells adherent to the
niche are less easily digested during isolation. This idea was
born from the initial observation [87] of the preferential
distribution of glioma stem cells in the perivascular area
(aberranttumorvasculature).CD133+/Nestin+cellsisolated
from glioblastoma, medulloblastoma, ependymomas, and
oligodendrogliomas migrate to and interact tightly with the
vascular tubes formed by endothelial cells. Furthermore,
cotransplanting tumor stem cells and endothelial cells into
immunocompromised mice, it was shown that endothelial-
derived factors (such as VEGF) accelerate the initiation and
the growth of brain tumors [87]. All these observations
are in addition to the fact that the niche has the ability to
dediﬀerentiate nontumorigenic cells into tumorigenic CSCs
[88, 89]. Hypoxia is a functional component of stem cell
niche, promoting the maintenance ofanundiﬀerentiated cell
state in normal tissues and in tumors. In hypoxic conditions,
nonstem glioma cells acquire self-renewal and long-term
proliferative potential, in addition to the expression of genes
related to stem cell functions. The tumor cell plasticity
induced by hypoxia is mainly regulated by hypoxia-inducible
factors (HIFs). Diﬀerential mRNA and protein expression
of HIF1α and HIF2α between nonstem and cancer stem
cells have been demonstrated, although both factors have
an essential role in promoting tumorigenesis. While HIF1α
is expressed in all neoplastic cells and neural progenitors,
HIF2α has a more speciﬁc function in cancer stem cells
with no expression in normal progenitors. HIFs are critical
to cancer stem cell maintenance and angiogenic drive, and
expression of HIF2α is signiﬁcantly associated with poor
glioma patient survival. This implies that targeting only
cancer stem cells may be insuﬃcient to improve patients’
outcomes because the nonstem cells may acquire stem cell
characteristics due to eﬀects of the microenvironment. Thus,
the malignant microenvironment might be targeted by
antiangiogenic therapies that would function via the disrup-
tion of stem cell maintenance.
Further insights are provided by the observation that
glioblastoma stem-like cell progeny may not be conﬁned to
the neural lineage. De Maria’s group demonstrated that a
proportion of endothelial cells contributing to blood vessels
inGBMoriginatesfromthetumoritself,directlydiﬀerentiat-
ing from the tumor stem-like cells as a set of endothelial cells
lining tumor vessels carry genetic abnormalities found in the
tumor cells themselves [7]. Another interesting study [90]
showed that the diﬀerentiation of tumor stem-like cells into
endothelial cells might be mediated initially by the Notch
pathway for the diﬀerentiation in endothelial progenitor
cells and subsequently by the vascular-endothelium-growth-
factor- (VEGF-) signaling pathway, selectively aﬀecting the
diﬀerentiation of endothelial progenitors to tumor-derived
endothelial cells.
The connection between neural stem cells and the endo-
thelial compartment seems to be critical in glioblastoma,
where cancer stem cells closely interact with the vascular
niche and promote angiogenesis.
9. Side Population
Some stem cells may additionally express ABC transporters,
responsible for multidrug resistance. ATP binding (ABC)
cassette transporters, able to pump the ﬂuorescent dye
HOECHST-33342 out of the cell [91], identify unlabelled
“side population” (SP) highly enriched in stem cells in many
tissues, including neural [92, 93]. The capacity to eject
the dye HOECHST-33342 is based on ABCG2 expression,
a multidrug resistance protein that is expressed in stem
cells but not in downstream progenitors and thus deﬁnes
an SP population highly enriched in stem cells in various
tissues [94]. A growing body of evidence suggests that GBM
and gliomas in general arise from the “side population”
subset of cells. The SP fraction isolated from the C6 glioma
cell line exhibited the stem cell properties of self-renewal
and multipotency and could reform more diﬀerentiated SP-
negative cells characteristic of the original cell line. These
SP-positive cells were also tumorigenic in vivo, whereas SP-
negative cells were not [95]. In a mouse model of glioma,
it has been demonstrated that CSCs are enriched in the SP
[96]. This cellfraction isolated from diﬀerent primary tumor
cells is able to sustain expansion ex-vivo and to generate SP
andnon-SPprogeny[97].TheSPisolatedfrombraintumors
is capable of neurospheres formation with self-renewal and
diﬀerentiation potential, is chemoresistant, and expresses
high levels of drug-transporters proteins such as MDR-1,
MRP-1, and ABCG2 [98]. However, there are conﬂicting
data showing that either the sorted SP or non-SP cells were
similarly clonogenic in vitro and equally tumorigenic in vivo.
In addition, when culturing SP and non-SP cells, it has been
demonstratedingastrointestinalcancercelllinesthatthetwo
populations are interconvertible, each giving rise to the other
[99], even though they represent phenotypically diﬀerent
populations.
Several questions need to be answered regarding the role
of ABCG2 in glioma biology. The Holland group has shed
light on the ABCG2 activity and the resulting SP phenotype
showing that ABCG2 function and localization to the plasma
membrane are regulated by the PI3K and Akt pathways.
Moreover, ABC transporter’s function is lost in glioma en-
dothelial cells, correlating with the blood brain barrier loss
of integrity seen in glioma patients [100].
The same group previously investigated the role of nitric
oxide (NO) activity in the perivascular niche using a mouse
genetic model of PDGF-induced gliomas [101]a n df o u n d
that eNOS (endothelial nitric oxide synthase) expression is
elevated in the tumor vasculature adjacent to the glioma
cells, and the Notch signaling driven by NO/cGMP pathway
induces the SP phenotype in primary glioma cell cultures.
The production of nitric oxide was shown to increase neu-
rosphere-forming capacity and the in vivo tumorigenic
capacity of PDGF-driven glioma primary cultures, while its
suppression prolongs mice survival. Even if the contribution
of aberrant NO signaling within the niche is obviously not
the only contribution to gliomagenesis, its role in tumor
angiogenesis, and the involvement of the perivascular niche
in the disease process, it is worthy of further investigation as
a potential therapeutic target.6 Journal of Oncology
10.HighALDHActivityas
aFunctionalMarker to IsolateCSCs
Acomplementarystrategyforthefunctionalidentiﬁcationof
normal stem cells and their malignant counterparts involves
the measurement of aldehyde dehydrogenase (ALDHs)
activity. Aldehyde dehydrogenases (ALDH) are a family of
enzymes that eﬃciently detoxify aldehydic products gener-
ated by reactive oxygen species and might therefore partic-
ipate in cell survival. ALDH enzymes activity is important
for drug resistance, cell proliferation, diﬀerentiation, and
the response to oxidative stress [102–104]. High ALDH
activity has been used to identify and select stem-like subsets
in hematopoietic cells [105], endothelial progenitor cells,
and mesenchymal and epithelial stem cells [106–108]. It is
becoming increasingly clear that ALDH activity can be used,
either alone or in combination with cell surface markers,
to identify CSCs in hematologic malignancies and various
solid carcinomas such as colon, breast, and lung [102, 103,
109, 110]. A group of investigators adopted the complex
ﬂuorescence-activated cell sorting based on high ALDH
enzyme activity to select tumor-initiating cells, which corre-
lates with enhanced clonogenicity and invasiveness in vitro
[111, 112]. This isolation approach might present advan-
tages: whilst the surface phenotype of a stem cell may remain
stable over time, the functional activity may decline.
Moreover, it has been shown that ALDH1 inhibition
induces diﬀerentiation in vitro and reduces clonogenicity
[113]. Consequently, ALDH1 activity might be a functional
correlate of an undiﬀerentiated state of glioma cells capable
of growing in neurospheres and appears to confer speciﬁc
advantage to stem cells despite the fact that the molecular
nature of this advantage is not yet clear. Therefore, detection
of ALDH activity as a puriﬁcation strategy might render
the identiﬁcation more reliable and with a high level of
experimental reproducibility.
11.CellMigration AbilityasaPotentialCSCs
Isolation Method
We should also consider the hypothesis [114] to isolate
and enrich cancer stem cell based on the heterogeneity
of invasiveness of tumoral cells, according to the ﬁndings
that the CSCs possess more inﬁltrative capability than their
progeny [115].
12. Dye-Based Marker-IndependentMethod to
SegregateCSCs
An alternative approach to investigate tumor-initiating
potentialingliomasexploitsintrinsicautoﬂuorescenceprop-
erties and distinctive morphology of human glioma cells
[116]. This method can discern a subpopulation of human
cells displaying autoﬂuorescence around 520nm upon laser
excitation at 488nm. Moreover, the same fraction retains
spherogenic potential for at least 5 passages (yielding spheres
with bigger size), while nonﬂuorescent cells lose their clon-
ogenic capacity between passages 3 and 4. In addition to
their enhanced self-renewal and multipotency, these auto-
ﬂuorescent cells also are highly tumorigenic as injection of as
few as 3000 cells per mouse consistently yielded tumors. The
molecular basis of this autoﬂuorescence is unknown, but it
probably reﬂects higher metabolic and proliferative activity.
Theidentiﬁcationofadye-retainingbraintumorpopula-
tion enables the identiﬁcation of a subpopulation displaying
the hallmarks of a tumor-initiating subpopulation. Several
groups have recently shown that the isolation of a label-
retaining cell fraction bearing robustly identiﬁes cancer stem
cells from solid tumors such as breast [117], skin [63],
and pancreatic [118] cancers. To determine if such pop-
ulation exists in GBM as well, the Vescovi and Reynolds’
groups [119] exploited the properties of CFSE (the prodrug
carboxyﬂuorescein diacetate succinimidyl ester), which is
converted by cellular esterase activity into a ﬂuorescent
compound covalently bound to proteins and retained within
the cells. Since the dye is equally divided between daughter
cells after division, it is possible to follow label retention and
the decreasing ﬂuorescence intensity with time. The authors
observed that bright cells dilute the dye signiﬁcantly slower
than the overall population, exhibiting a lower frequency of
cell division, and that these cells constitute a label-retaining
population of glioma-initiating cells. Moreover, this cell
fraction carries a greater tumor-initiation ability in vivo and
displays migratory and inﬁltration capability. These observa-
tions are in agreement with the hypothesis that cancer stem
cells are a slow-cycling, infrequent population endowed with
the self-renewal and multipotent diﬀerentiation features of a
stem cell.
13. Conclusion
Theseresultssupportthephenotypicdiversityoftumorcells,
and the cellular phenotype strongly correlated with stemness
and tumorigenic capacity. It is conceivable that subpopula-
tions grouped by markers expression such as CD133, CD15,
L1CAM, or integrin α6, for instance, represent distinct
functional entities that contribute to the phenotypes of
human GBMs which thus far cannot be encompassed by a
single CSC marker. Considering the inconsistency between
stem cell markers, there is a need to deﬁne CSCs using more
precise functional markers, for example, by receptors for
growth or chemotactic factors involved in stem cells main-
tenance or diﬀerentiation.
Thus, the heterogeneity observed in brain tumors may
be correlated to the diversity on a cellular level, in which dif-
ferent subpopulations of glioma cells are dedicated towards
diﬀerent functional roles.
Given the complex genetic and epigenetic heterogeneity
of GBMs, it is unlikely that the expression of a single marker
will deﬁne CSCs in every tumors; hence, a combination
of markers will probably best deﬁne glioma tumor stem
cells. Furthermore, the ability to molecularly determine this
characteristic may permit the development of more tailored
brain cancers treatment.
Although several markers show promises and good
potential in early studies, the lack of reliable data (caused
by a lack of standardized approaches regarding methods forJournal of Oncology 7
GBM-derived cells isolation and the procedure adopted for
deﬁning “stemness”) makes their clinical value diﬃcult to
determine.
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